Chiral organometallic compounds

ABSTRACT

A chiral, organometallic compound which, at a molecular level, has no C2 symmetry and comprises a carbon to carbon bond joining a chiral carbon atom to a carbon atom of a cyclopentadiene ring that is non-symmetrically substituted. Examples of such compounds include compounds of formula (I): ##STR1## wherein X 1  and X 2  are, independently, groups which are removable during a chemical reaction; M is titanium, zirconium or hafnium; and R 1-8 ,11 are as specified in the description.

This application is the national phase of international application PCT/GB96/00264, filed Feb. 6, 1996 which was designated the U.S.

The present invention relates to organometallic, chiral compounds useful in asymmetric synthesis, to processes for preparing said compounds and to a method of using them in industrial processes to produce chiral products.

Various organometallic, chiral compounds are known for asymmetric synthesis (such as from DE4218199).

The present invention provides a chiral, organometallic compound which, at a molecular level, has no C2 symmetry and comprises a carbon to carbon bond joining a chiral carbon atom to a carbon atom of a cyclopentadiene ring that is non-symmetrically substituted. By having a cyclopentadienyl ring that is not symmetrically substituted the organometallic compound possesses planar chirality and by having a chiral group attached to the non-symmetrically substituted cyclopentadiene ring the faces of the cyclopentadiene are diastereotopic. Also, once complexed to the metal of the organometallic compound, the non-symmetrically substituted cyclopentadiene ring provides two control elements for enantioinduction.

In one aspect the present invention provides a compound of formula (I), wherein X¹ and X² are, independently, groups which are removable during a chemical reaction; M is titanium, zirconium or hafnium; and (a) R⁸ and R¹¹ are hydrogen; R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with hydroxy, trialkylsilyl, alkyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³, R⁴, R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R¹ ; R⁴, R⁵, R⁶ and R⁷ may also be, independently, hydrogen; or, one or more of R³ and R⁴, R⁴ and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally substituted silyl bridge; or (b) R³ and R⁸ or R¹, R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms; or R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; one of R⁴ and R¹¹ must be hydrogen the other being selected from the substituents already recited for R² apart from hydrogen; R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R² ; or, one or more of R⁴ or R¹¹ (whichever is not hydrogen) and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁷ or R⁴ or R¹¹ (whichever is not hydrogen) joins with R⁵ to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge.

Alkyl groups and the alkyl part of alkoxy groups have straight or branched chains. They preferably contain from 1 to 10, especially 1 to 6 (for example 1 to 4) carbon atoms, and are, for example, methyl, ethyl, iso-propyl, tert-butyl or n-hexyl. Alkyl and alkoxy groups are optionally substituted, especially optionally substituted by trialkylsilyl or alkoxy.

Aryl includes naphthyl but is preferably phenyl.

Trialkylsilyl groups are especially C₁₋₈ alkyl₃ Si, for example (CH₃)₃ Si.

Cycloalkyl and cycloalkenyl rings preferably contain from 3 to 8, especially from 3 to 6, carbon atoms. They are, for example, cyclopropyl, cyclopentyl, cyclohexyl or cyclohexenyl. Cycloalkyl and cycloalkenyl rings are optionally substituted by hydroxy, alkoxy, alkyl, aryl or arylalkyl groups.

Arylalkyl is preferably phenyl(C₁₋₄)alkyl and is, for example, benzyl, 1-phenyleth-1-yl, 2-phenyleth-1-yl, 2-phenylprop-2-yl, 1-phenylprop-2-yl or 1-phenyl-2-methylprop-2-yl.

Aryloxyalkyl is preferably phenoxy(C₁₋₄)alkyl and is, for example, phenoxymethyl or 1- or 2-phenoxyethyl.

Alkoxyalkyl and alkoxyalkoxyalkyl are preferably C₁₋₆ alkoxy(C₁₋₆)alkyl and C₁₋₆ alkoxy(C₁₋₆)alkoxy(C₁₋₆)alkyl respectively. They are, for example, methoxymethyl, ethoxymethyl or methoxy(ethoxymethyl).

Cycloalkylalkyl is preferably C₃₋₈ cycloalkyl(C₁₋₄)alkyl and is, for example, cyclopropylmethyl, cyclohexylmethyl or cyclohexylethyl.

Heterocyclyl rings are not aromatic and preferably contain from 3 to 8, especially from 3 to 6, atoms selected from the group comprising carbon, oxygen, nitrogen or silicon. It is preferred that the rings contain 1, 2 or 3 heteroatoms. Heterocyclyl rings are, for example, piperidine, morpholine or pyrrolidine; and are, preferably, optionally substituted by hydroxy, alkoxy, alkyl, aryl or arylalkyl groups.

Heteroaryl includes aromatic 5 or 6 membered rings comprising one or more (preferably 1, 2 or 3) heteroatoms (preferably nitrogen, oxygen or sulphur). Heteroaryl is, for example, pyridine, pyrimidine, triazine (1,2,3-, 1,2,4- or 1,3,5-), pyrrole, quinoline or isoquinoline.

Heteroarylalkyl is preferably heteroaryl(C₁₋₄)alkyl and is, for example, pyrid-2-ylmethyl or pyrid-4-ylmethyl.

Heteroaryloxyalkyl is preferably heteroaryloxy(C₁₋₄)alkyl and is, for example, pyrid-2-yloxymethyl or pyrid-4-yloxymethyl.

When R³, R⁴, R⁷ or R¹¹ joins with R⁵ to form a bridge, optionally substituted C₁₋₃ alkyl is especially C₁₋₃ optionally substituted with alkyl or phenyl (for example the bridge is CH₂, CH₂ CH₂, CH(CH₃)CH₂ or (CH₂)₃) and optionally substituted silyl is especially di(C₁₋₄ alkyl)silyl (such as (CH₃)₂ Si), diarylsilyl (such as (C₆ H₅)₂ Si) or monoarylmono(C₁₋₄ alkyl)silyl (such as (CH₃)(C₆ H₅)Si). The bridge formed is especially CH₂ CH₂ or (CH₃)₂ Si.

All aryl and heteroaryl groups are optionally substituted by one or more substituents. Preferred substituents are halogen, hydroxy, mercapto, C₁₋₈ alkyl (especially methyl or ethyl), C₁₋₈ alkoxy (especially methoxy), C₁₋₄ alkylthio (especially methylthio), hydroxy(C₁₋₄)alkyl, C₁₋₄ alkoxy(C₁₋₄)alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, optionally substituted methylenedioxy or ethylenedioxy (for example optionally substituted by alkyl) or --NR'R", in which R' and R" are independently hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, phenyl or benzyl, the phenyl and benzyl groups being optionally substituted with C₁₄ alkyl or C₁₋₄ alkoxy.

In another aspect the present invention provides a compound of formula (Ia) wherein R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with hydroxy, trialkylsilyl, alkyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³, R⁴, R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R¹ and R² ; or R³ and R⁴ or R⁵ and R⁶ or both join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R⁴, R⁵, R⁶ and R⁷ may also be, independently, hydrogen; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally substituted silyl bridge; X¹ and X² are, independently, groups which are removable during a chemical reaction; and M is titanium, zirconium or hafnium.

In yet another aspect the present invention provides a compound of formula (Ia) wherein R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³, R⁴, R⁵ and R⁶ are the same or different and are selected from the substituents already recited for R¹ and R², or, R³ and R⁴ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R⁴, R⁵ and R⁶ may also be, independently, hydrogen; R⁷ is hydrogen or alkyl; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally substituted silyl bridge; X¹ and X² are, independently, groups which are removable during a chemical reaction; and M is titanium, zirconium or hafnium.

In another aspect the present invention provides a compound of formula (Ia) in which R³ and R⁴ or R⁵ and R⁶ join to form an optionally substituted unsaturated (for example aromatic) or, preferably, saturated ring. The ring optionally comprises one or more heteroatoms (such as nitrogen), but is preferably carbocyclic.

In a further aspect the present invention provides a compound of formula (Ia) in which R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring.

In yet another aspect the present invention provides a compound of formula (Ia) wherein R³ is C₁₋₄ alkyl (especially methyl), R⁴ is hydrogen or C₁₋₄ alkyl (especially methyl or tert-butyl), or R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 5, 6 or 7 membered carbocyclic ring (such as a 6 membered aromatic ring), and R⁷ is hydrogen or C₁₋₄ alkyl (such as methyl or tert-butyl).

In a further aspect the present invention provides a compound of formula (Ia) wherein R¹ is C₁₋₄ alkyl (such as iso-propyl or tert-butyl), phenyl, tri(C₁₋₄)alkylsilyl (such as trimethylsilyl) or phenyl(C₁₋₄)alkyl (such as 2-phenylprop-2-yl); and R² is C₁₋₄ alkyl (such as methyl).

In a still further aspect the present invention provides a compound of formula (Ia) wherein R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl ring (such as cyclopropyl, cyclopentyl or cyclohexyl) optionally substituted with alkyl (such as methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl) or phenylalkyl (such as benzyl, 1-phenyleth-1-yl, 2-phenyleth-1-yl, 2-phenylprop-2-yl, 1-phenylprop-2-yl or 1-phenyl-2-methylprop-2-yl).

In another aspect the present invention provides a compound of formula (Ia) in which R⁷ is hydrogen.

In a still further aspect the present invention provides a compound of formula (Ia) wherein R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl ring (such as cyclopropyl, cyclopentyl or cyclohexyl) optionally substituted with alkyl (such as methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl) or phenylalkyl (such as benzyl, 1-phenyleth-1-yl, 2-phenyleth-1-yl, 2-phenylprop-2-yl, 1-phenylprop-2-yl or 1-phenyl-2-methylprop-2-yl); R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring; R⁵, R⁶ and R⁷ are all hydrogen; and X¹ and x² are, independently, chlorine or bromine.

In another aspect the present invention provides a compound of formula (II) or (II') or an enantiomer thereof, wherein R⁵ is hydrogen or C₁₋₄ alkyl (especially methyl); M is zirconium, titanium or hafnium (but is preferably zirconium); Y¹ is C₁₋₄ alkyl (especially methyl, iso-propyl or tert-butyl), tri(C₁₋₄)alkylsilyl (especially trimethylsilyl) or phenyl(C₁₋₄)alkyl (especially 2-phenylprop-2-yl); Y², Y³, Y⁴, Y⁵, Y⁶ and Y⁷ are all hydrogen; Y⁸ and Y⁹ are, independently, hydrogen or C₁₋₄ alkyl (especially methyl or iso-propyl); and Y¹⁰ is hydrogen, C₁₋₄ alkyl (especially methyl or iso-propyl) or tri(C₁₋₄ alkyl)silyl (especially trimethylsilyl).

In a further aspect the present invention provides a compound of formula (Ib), wherein X¹ and X² are, independently, groups which are removable during a chemical reaction; M is titanium, zirconium or hafnium; R³ and R⁸ or R¹, R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms; or R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; one of R⁴ and R¹¹ must be hydrogen the other being selected from the substituents already recited for R² apart from hydrogen; R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R² ; or, one or more of R⁴ or R¹¹ (whichever is not hydrogen) and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁷ or R⁴ or R¹¹ (whichever is not hydrogen) joins with R⁵ to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge. Examples compounds of formula (Ib) are compounds of formulae (IIa)-(IIg), wherein R⁹ and R¹⁰ are, independently, hydrogen or alkyl, and other variables are as defined earlier in this paragraph.

The ring system formed when R³ and R⁸ or R¹, R³ and R⁸ join is, preferably, a mono- or bi-cyclic ring system (such as the ring systems shown in formulae (IIa)-(IIg)). Preferred substituents on the ring system are alkyl, aryl or arylalkyl. Preferred heteroatoms in the ring system are oxygen, sulphur or nitrogen. When it is present, it is preferred that the nitrogen atom is optionally substituted by alkyl.

In another aspect the present invention provides a compound of formula (Ib), wherein X¹ and X² are, independently, groups which are removable during a chemical reaction; M is titanium, zirconium or hafnium; R³ and R⁸ or R¹, R³ and R¹ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms; or R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R⁴ is hydrogen; R¹¹ is selected from the substituents already recited for R² apart from hydrogen; R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R² ; or, one or more of R¹¹ and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁷ or R¹¹ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge.

In yet another aspect the present invention provides a compound of formula (Ib), wherein X¹ and X² are, independently, groups which are removable during a chemical reaction; M is titanium, zirconium or hafnium; R³ and R⁸ or R¹, R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms, or R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R¹¹ is hydrogen; R⁴ is selected from the substituents already recited for R² apart from hydrogen; R⁵, R⁶ and R⁷ are the same or different and are selected from the substituents already recited for R² ; or, one or more of R⁴ and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁷ or R⁴ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge.

In a still further aspect the present invention provides a compound of formula (Ib) wherein when R¹¹ is hydrogen R⁴ and R⁷ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring; or when R⁴ is hydrogen R¹¹ and R⁷ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring.

In another aspect the present invention provides a compound of formula (Ia), or an enantiomer thereof, wherein X¹ and X² are halogen (especially chlorine); M is titanium or zirconium; one of R⁴ and R¹¹ is hydrogen the other being C₁₋₆ alkyl (especially methyl, ethyl or tert-butyl) or phenyl; R⁷ is hydrogen, C₁₋₆ alkyl (especially methyl, ethyl or tert-butyl) or phenyl; or R⁴ or R¹¹ (whichever is not hydrogen) and R⁷ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6-membered non-aromatic carbocyclic ring.

In yet another aspect the present invention provides a compound of formula (I) (especially a compound of formula (Ia) or (Ib)) in which R⁵ and R⁶ are both hydrogen.

In yet another aspect the present invention provides a compound of formula (I) (especially a compound of formula (Ia) or (Ib)) in which X¹ and X² are, independently, halogen (preferably chlorine or bromine), alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl or aryloxy.

Alkenyl and alkynyl groups have straight or branched chains. They preferably contain from 2 to 10, especially from 2 to 6 (such as 2 to 4) carbon atoms, and are, for example, vinyl, allyl or propargyl. Alkenyl and alkynyl groups are optionally substituted by aryl.

In yet another aspect the present invention provides a compound of formula (I) (especially a compound of formula (Ia) or (Ib)) in which X¹ and X² are, independently, halogen.

In a further aspect the present invention provides a compound of formula (I) (especially a compound of formula (Ia) or (Ib)) in which M is zirconium.

The compounds of Tables I to XXVI illustrate the invention.

                  TABLE I     ______________________________________     All the compounds of Table I are of formula (II)     wherein M is zirconium and R.sup.5 is hydrogen.     Compound     No.     Y.sup.1                    Y.sup.2                          Y.sup.3                              Y.sup.4                                  Y.sup.5                                       Y.sup.6                                           Y.sup.7                                               Y.sup.8                                                    Y.sup.9                                                         Y.sup.10     ______________________________________     1       Pr.sup.i                    H     H   H   H    H   H   CH.sub.3                                                    H    H     2       Pr.sup.i                    H     H   H   H    H   H   H    CH.sub.3                                                         H     3       Bn     H     H   H   H    H   H   CH.sub.3                                                    H    H     4       Bu.sup.t                    H     H   H   H    H   H   CH.sub.3                                                    H    H     5       Pr.sup.i                    H     H   H   H    H   H   Pr.sup.i                                                    H    H     6       Bn     H     H   H   H    H   H   Pr.sup.i                                                    H    H     7       Bu.sup.t                    H     H   H   H    H   H   Pr.sup.i                                                    H    H     8       Pr.sup.i                    H     H   H   H    H   H   H    H    H     9       Bn     H     H   H   H    H   H   H    H    H     10      Bu.sup.t                    H     H   H   H    H   H   H    H    H     11      CH.sub.3                    H     H   H   H    H   H   H    H    CH.sub.3     12      Pr.sup.i                    H     H   H   H    H   H   H    H    Pr.sup.i     13      SM     H     H   H   H    H   H   H    H    SM     ______________________________________      Pr.sup.i = (CH.sub.3).sub.2 HC      Bu.sup.t =(CH.sub.3).sub.3 C      Bn = C.sub.6 H.sub.5 (CH.sub.3).sub.2 C      SM = Si(CH.sub.3).sub.3

TABLE II

Table II comprises 13 compounds of formula (II) wherein R⁵ is hydrogen and M is titanium and Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compound in Table I.

TABLE III

Table III comprises 13 compounds of formula (II) wherein R⁵ is hydrogen and M is hafnium and Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compound in Table I.

TABLES IV TO VI

Each of Tables IV to VI comprises 13 compounds of formula (I) wherein R⁵ is methyl and M, Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸ Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compounds of Tables I to III respectively.

TABLES VII TO XII

Each of Tables VII to XII comprises 13 compounds. The compounds of these Tables are the enantiomers of the compounds of formula (II) of Tables I to VI respectively wherein R⁵, M, Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compounds of Tables I to VI.

TABLES XIII TO XVIII

Each of Tables XIII to XVIII comprises 13 compounds. The compounds of these Tables are compounds of formula (II') wherein R⁵, M, Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compounds of Tables I to VI.

TABLES XIX TO XXIV

Each of Tables XIX to XXIV comprises 13 compounds. The compounds of these Tables are the enantiomers of the compounds of formula (II') of Tables XIII to XVIII respectively wherein R⁵, M, Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹ and Y¹⁰ have the values listed for the correspondingly numbered compounds of Tables XIII to XVIII.

                  TABLE XXV     ______________________________________     Table XV comprises compounds of formula (IIa) wherein X.sup.1 and X.sup.2     are     both chlorine.     Compound     No.      R.sup.4   R.sup.7 R.sup.11                                      M    R.sup.5                                                 R.sup.6     ______________________________________     1        CH.sub.3  H       H     Zr   H     H     2        CH.sub.3  H       H     Ti   H     H     3        CH.sub.3  H       H     Zr   CH.sub.3                                                 H     4        CH.sub.3  H       H     Ti   CH.sub.3                                                 H     5        CH.sub.2 CH.sub.3                        H       H     Zr   H     H     6        CH.sub.2 CH.sub.3                        H       H     Ti   H     H     7        CH.sub.2 CH.sub.3                        H       H     Zr   CH.sub.3                                                 H     8        CH.sub.2 CH.sub.3                        H       H     Ti   CH.sub.3                                                 H     9        H         H       CH.sub.3                                      Zr   H     H     10       H         H       CH.sub.3                                      Ti   H     H     11       H         H       CH.sub.3                                      Zr   CH.sub.3                                                 H     12       H         H       CH.sub.3                                      Ti   CH.sub.3                                                 H     13       CH.sub.3  CH.sub.3                                H     Zr   H     H     14       CH.sub.3  CH.sub.3                                H     Ti   H     H     15       H         CH.sub.3                                CH.sub.3                                      Zr   CH.sub.3                                                 H     16       H         CH.sub.3                                CH.sub.3                                      Ti   CH.sub.3                                                 H     17       --(CH.sub.2).sub.4 -                            H       Zr   H     H     18       H         --(CH.sub.2).sub.4 -                                    Ti   H     H     19       H         --(CH.sub.2).sub.4 -                                    Zr   CH.sub.3                                               H     20       H         --(CH.sub.2).sub.4 -                                    Ti   CH.sub.3                                               H     21       H         --(CH.sub.2).sub.4 -                                    Zr   H     H     22       --(CH.sub.2).sub.4 -                            H       Ti   H     H     23       --(CH.sub.2).sub.4 -                            H       Zr   CH.sub.3                                               H     24       --(CH.sub.2).sub.4 -                            H       Ti   CH.sub.3                                               H     25       C.sub.6 H.sub.5                        H       H     Zr   H     H     26       C.sub.6 H.sub.5                        H       H     Ti   H     H     ______________________________________

TABLE XXVI

Tables XXVI comprises 26 compounds. The compounds of this Table are the enantiomers of the compounds of formula (IIa) of Table XXV wherein M, R⁴, R⁵, R⁶, R⁷ and R¹¹ have the values listed for the correspondingly numbered compounds of Table XXV.

The compounds of formula (I) can be prepared by one of the following procedures. References to compounds of formula (III) or (V) include all double bond isomers within the cyclopentadiene ring.

The compounds of formula (I) can be prepared by deprotonating a compound of formula (III) (for example with a butyllithium) in a suitable solvent (such as tetrahydrofuran) and reacting the product obtained with a compound of formula (IV) (wherein L is a suitable leaving group such as a halogen atom). Alternatively, the compounds of formula (I) can be prepared by deprotonating a compound of formula (V) (for example with a butyllithium) in a suitable solvent (such as tetrahydrofuran) and reacting the product obtained with a compound of formula (VI) (wherein L is a suitable leaving group such as a halogen atom).

The compounds of formula (I) can be prepared by reacting a trialkylsilyl or trialkylstannyl derivative of a compound of formula (III) with a compound of formula (IV) (wherein L is a suitable leaving group such as a halogen atom) in a suitable solvent (such as tetrahydrofuran). Alternatively, the compounds of formula (I) can be prepared by reacting a trialkylsilyl or trialkylstannyl derivative of a compound of formula (V) with a compound of formula (VI) (wherein L is a suitable leaving group such as a halogen atom) in a suitable solvent (such as tetrahydrofuran).

Alternatively, when R³ and R⁴ join to form a saturated, non-aromatic, carbocyclic ring, a compound of formula (I) can be prepared hydrogenating a compound of formula (I) wherein R³ and R⁴ join to form an aromatic ring under suitable conditions (such as with hydrogenation at room temperature, 1 bar (1 atmosphere; 760 mm Hg) using a suitable catalyst (such as platinum oxide) in a suitable solvent (such as dichloromethane)).

Alternatively, a compound of formula (I) wherein M is titanium can be prepared by carrying out any of the above processes on a titanium (III) derivative followed by oxidation.

Certain compounds of formula (I) (such as those wherein R³ and R⁴ form an saturated ring, and M is titanium) are preferably prepared by chemically modifying the nature the ligand incorporating R³ and R⁴ whilst the ligand is attached to zirconium, removing the ligand from zirconium (preferably by reacting the zirconium compound (which is preferably in solution (for example in a solution of an aromatic solvent, such as benzene)) with a suitable base (such as a hydroxide, for example sodium hydroxide)) and then attaching the ligand to a compound of formula (IV) using the methodology described above.

Compounds of formula (IV) are either know in the literature or can be prepared by suitable modification of literature methods (such as the method of Lund, E. C. et al in Organometallics (1990) 9 2426-7). Compounds of formula (III) are either known in the literature or can be prepared by suitable modification of literature methods (such as the method of Erker, G. in Journal American Chemical Society (1993) 115 4590). Compounds of formula (VI) are either known in the literature or can be prepared by suitable modification of literature methods (such as a combination of the methods referred to earlier). Compounds of formula (V) are either known in the literature or can be prepared by suitable modification of literature methods.

In further aspects the present invention comprises processes for preparing compounds of formulae (I) (especially compounds of formula (Ia) or (Ib)) and (II) and enantiomers thereof.

The compounds of the invention (especially the compounds of formulae (Ia) or (Ib)) can be used as catalysts in a variety of different industrial processes from which chiral products are required. Examples of such processes are hydride transfers (such as hydrogenations of chain or cyclic alkenes, imines or enarines), the preparation of secondary alcohols from ketones, the catalytic asymmetric carbomagnesiation or carboalumination of alkenes (resulting in good enantiomeric excesses), the intermolecular dimerisation of alkenes, the intramolecular co-cyclisation of 1,n-dienes, the intramolecular co-cyclisation/elimination of an alkene with an alkene carrying an allylic leaving group, the alkylation of heteroaromatic (such as pyridines, quinolines or isoquinolines) with alkenes or the Ziegler Natta type polymerisations or oligomerisations of alkenes.

Alternatively, the compounds of the invention (especially the compounds of formulae (Ia) or (Ib)) can be used stoichiometrically in a variety of different industrial processes from which chiral products are required. Examples of such processes are trapping of zirconocene η² -imine complexes, cocyclisation of enynes or dienes, addition of in situ formed zirconocene η² -alkene complexes to alkenes, alkynes or ketones, addition of in situ formed zirconocene η² -benzyne complexes to alkenes, aldehydes or imines, or addition of in situ formed zirconocene η² -alkyne complexes to alkenes, aldehydes or imines.

An important advantage of using the compounds of formulae (Ia) or (Ib) in the processes given above is that the compounds of formulae (Ia) or (Ib) are recoverable at the end of such processes and do not lose their chirality during the course of the process in which they are used.

The compounds of the invention (especially the compounds of formulae (Ia) or (Ib)) can be used in the above processes in free molecular form or bound to a polymer support. For example, a compound of formula (Ia) can be attached to a polymer support through either cyclopentadiene ring (especially the ring carrying the substituents R⁵ and R⁶), a compound of formula (II) or (II') having at least one of Y³ Y⁴, Y⁵, Y⁶, Y⁷, Y⁸, Y⁹, or Y¹⁰ as alkyl, can be attached to a polymer support through said alkyl group. Suitable polymer supports include polymers derived from cross linked polystyrene. Examples of compounds of the invention bound to a polymer support are presented as structures (A), (B) and (C). In these structures the encircled letter P denotes a polymer support. A compound of formula (Ib) can, by analogy, be attached to a polymer support through either a cyclopentadiene ring or through an alkyl group.

The following Examples illustrate the invention. All NMR data is expressed in ppm from tetramethylsilane. Throughout the Examples the following abbreviations are used:

    ______________________________________     THF = tetrahydrofuran                      NMR = Nuclear Magnetic Resonance     ppm = parts per million                      s = singlet     d = doublet      m = multiplet     t = triplet      q = quartet     dd = doublet of doublets                      dt = doublet of triplets     brs = broad singlet                      ddd = doublet of doublet of doublets     mp = melting point                      DME = dimethoxyethane     eq = equivalents     HMPA = hexamethylphosphoramide ((CH.sub.3).sub.2 N).sub.3 PO     CpZrCl.sub.3 = cyclopentadienyl zirconium trichloride     ______________________________________

CpZrCl₃.DME may be prepared by the method of Lund, E. C. et al in Organometallics (1990) 9 2426-7.

EXAMPLE 1

This Example illustrates the preparation of (cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (Compound No. 1 in Table VII).

(+)-3- (1'S,2'S,5'R)-2'-isoPropyl-5'-metliylcyclohexyl!indene (1.017 g, 4 mmol, 1 eq) was dissolved in THF (10 ml) and cooled to -78° C. n-Butyllithium (1.6 ml of 2.5 M solution in hexanes, 4 mmol, 1 eq) was added and the orange solution stirred at room temperature for two hours. This solution was then added to a suspension of CpZrCl₃.DME in THF (10 ml) at room temperature. The bright yellow solution was stirred overnight before the solvent was removed in vacuo and the residue redissolved in dichloromethane (10 ml). Platinum oxide (90 mg, 0.4 mmol, 10%) was added and the mixture was stirred under an atmosphere of hydrogen gas (1 bar) overnight. The colourless solution was filtered through CELITE™ and the solvent removed to furnish the title material as a pale solid (738 mg, 38%). The product was recrystallised from hot toluene to furnish clear block crystals. mp 237-238° C.

¹ H NMR (300 MHz; CDCl₃): δ 6.46 (d,1H), 6.44(s,5H), 5.58(d,J=2.9 Hz,1H), 3.07(m,1H), 2.88(m,2H), 1.00-1.95(m,18H), 0.98(d,J=6.6 Hz,3H), 0.73(d,J=0.38(d,J=6.9 Hz,3H)ppm.

¹³ C NMR (75.5 MHz; CDCl₃): δ 137.8(s), 137.2(s), 131.7(s), 114.8(d), 110.0(d), 102.9(d), 47.6(d), 39.4(t), 36.4(d), 33.6(t), 29.0(d), 28.9(d), 24.9(t), 24.5(t), 24.1(q), 22.5(t), 22.2(t), 22.1(t), 21.9(q), 18.5(q)ppm.

EXAMPLE 2

This Example illustrates the preparation of (cyclopentadienyl)(1- (1'R,2'R,5'S)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (Compound No. 1 of Table I).

Indene (6.156 g, 53 mmol, 11.1 eq) was dissolved in THF (50 ml). The solution was cooled to -78° C. and n-butyllithium (21.2 ml, of 2.5M solution in hexanes, 53 mmol, 1.1 eq) added. The orange solution was allowed to warm to room temperature and was stirred for one hour. After recooling to -78° C., (+)-(1S,2R,5S)-2-isopropyl-5-methylcyclohexan-1-ol p-toluenesulphonate ((+) menthol tosylate; 15.0 g, 48 mmol, 1 eq) in THF (50 ml) was added followed by HMPA (17.2 g, 96 mmol, 2 eq). The solution was allowed to warm slowly to room temperature and was stirred overnight. Water (100 ml) was added and the product extracted into diethylether (3×75 ml). After drying over MgSO₄ the solvent was removed in vacuo. The product was purified by column chromatography (eluant petroleum ether) followed by Kugelrohr distillation (155° C., 0.4 mbar) to yield (-)-3- (1'R,2'R,5'S)-2'-isopropyl-5'-methylcyclohexyl!indene as a white crystalline solid (1.036 g, 8.5%).

¹ H NMR (300 MHz; CDCl₃): δ 7.56 (d,J=7.5 Hz,1H), 7.48 (d,J=8.1 Hz,1H), 7.40(t,J=7.5 Hz,1H), 7.29(t,J=7.5 Hz,1H), 6.46(s,1H), 3.45(s,2H), 1.33-1.92(m,9H), 1.02(d,J=6.6 Hz,3H), 0.88(d,J=6.6 Hz,3H), 0.82(d,J=6.6 Hz,3H)ppm.

¹³ C NMR (75.5 MHz; CDCl₃): δ 146.8(s), 144.8(s), 143.9(s), 129.6(d), 126.2(d), 124.5(d), 123.8(d), 119.0(d), 47.8(d), 39.8(t), 38.6(t), 35.8(t), 34.3(d), 30.3(d), 27.5(t), 27.0(d), 22.6(q), 21.8(q), 21.6(q)ppm.

(-)-3- (1'R,2'R,5'S)-2'-isoPropyl-5'-methylcyclohexyl!indene (1.017 g, 4 mmol, 1 eq) was dissolved in THF (10 ml) and cooled to -78° C. n-Butyllithium (1.6 ml of 2.5 M solution in hexanes, 4 mmol, 1 eq) was added and the orange solution stirred at room temperature for two hours. This solution was then added to a suspension of CpZrCl₃.DME in THF (10 ml) at room temperature. The bright yellow solution was stirred overnight before the solvent was removed in vacuo and the residue redissolved in dichloromethane (10 ml). Platinum oxide (90 mg, 0.4 mmol, 10%) was added and the mixture was stirred under an atmosphere of hydrogen gas (1 bar) overnight. The colourless solution was filtered through CELITE™ and the solvent removed to furnish the title material as a pale solid (0.521 g, 27%). The product was recrystallised from hot toluene. mp 237-238° C.

EXAMPLE 3

This Example illustrates the preparation of (cyclopentadienyl)(1- (1'-R,2'R,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (Compound No. 2 of Table I).

(+)-3- (1'R,2'R,5'R)-2'-isoPropyl-5'-methylcyclohexyl!indene (1.017 g, 4 mmol, 1 eq) was dissolved in THF (10 ml) and cooled to -78° C. n-Butyllithium (1.6 ml of 2.5 M solution in hexanes, 4 mmol, 1 eq) was added and the orange solution stirred at room temperature for two hours. This solution was added to a suspension of CpZrCl₃.DME in THF (10 ml) at room temperature. The yellow solution was stirred overnight before the solvent was removed in vacuo and the residue redissolved in dichloromethane (10 ml). Platimum oxide (90 mg, 0.4 mmol, 10%) was added and the mixture was stirred under an atmosphere of hydrogen gas (1 bar) overnight. The colourless solution was filtered through CELITE™ and the solvent removed to furnish the title material as a pale solid (641 mg, 33%). mp 209-212° C.

¹ H NMR (300 MHz; CDCl₃): δ 6.42 (s,5H), 6.13(d,J=2.6 Hz, 1H), 5.63(d,J=2.8 Hz,1H), 2.73-3.00(m,3H), 2.51(m,2H), 1.10-1.65(m,24H), 0.94(d,J=6.1 Hz,3H), 0.85(d,J=6.6 Hz,3H), 0.31(d,J=6.2 Hz,3H)ppm.

¹³ C NMR (75.5 MHz; CDCl₃): δ 139.9(s), 138.5(s), 129.9(s), 114.8(d), 106.6(d), 102.3(d), 41.7(d), 40.6(d), 35.3(t), 32.6(d), 30.7(t), 29.4(t), 25.6(d), 24.9(t), 24.4(q), 23.8(t), 23.2(q), 22.6(t), 21.8(t), 21.7(q)ppm.

EXAMPLE 4

This Example illustrates the preparation of (cyclopentadienyl)(1- (1'S,2'S,5')-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl) titanium dichloride (Compound No. 1 in Table VIII).

Step 1: Preparation of (+)-3 (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!4,5,6,7-tetrahydroindene {3-Neomenthyltetraliydroindene}.

(Cyclopentadienyl)(neomenthyltetrahydroindenyl)zirconium dichloride (1.058 g, 2.2 mmol, prepared as in Example 1) was dissolved in benzene (10 mL) and stirred with sodium hydroxide (10 ml, 5 M) under an inert atmosphere. After 2 hours the organic phase was separated and the aqueous phase extracted with ethyl acetate (4×50 ml). The combined organics were dried and the solvent removed to yield a yellow oil. The product was purified by column chromatography (eluant petroleum ether) to furnish the product of step 1 as a white low melting solid (0.426 g, 83%). mp 39-41° C. (crystallised from pentane).

¹ H NMR (300 MHz; CDCl₃): δ 5.95(s,1H), 2.88(s,1H), 2.80(s,1H), 2.34(s,1H), 2.22(s,1H), 0.74-1.90(m,25H); including 1.71(`quin.`, J=3.0 Hz,1H), 0.89(d, J=6.6 Hz,3H), 0.82(d,J=5.9 Hz,3H), 0.75(d,J=5.9 Hz,3H)ppm. ¹³ C NMR (75.5 MHz; CDCl₃): δ 147.5(s), 139.9(s), 138.7(s), 124.5(d), 47.9(d), 45.2(t), 40.3(t), 35.7(t), 34.3(d), 29.6(d), 26.9(t), 25.9(d), 25.8(t), 24.0(t), 23.4(t), 23.2(t), 22.7(q), 21.6(q), 21.5(q)ppm.

Step 2: Preparation of title compound.

Neomenthyltetrahydroindene (300 mg, 1.2 mmol, 1 equivalent; as prepared in step 1) was dissolved in tetrahydrofuran (6 ml) and cooled in an ice bath. n-Butyllithium (0.48 ml of 2.5 M solution in hexanes, 1.2 mmol, 1 equivalent) was added dropwise and the pale yellow solution stirred at room temperature for 2 hours. This solution was then added to a solution of cyclopentadienyltitanium trichloride (250 mg, 1.14 mmol, 0.95 equivalent) in tetrahydrofuran (6 ml) at -78° C. A red solution was immediately formed. The reaction was allowed to warm slowly to room temperature and the solvent was removed to yield a red solid. The product was purified by column chromatography (eluant benzene) and furnished as a mixture of isomers (0.427 g, 85%). The major isomer could be separated by double recrystallisation from hot toluene.

major isomer (Compound No. 1 in Table VIII):

mp 220-222° C. (recrystallised from toluene);

¹ H NMR (360 MHz; CDCl₃): δ 6.46(s,5H), 6.16(d,J=3.0 Hz,1H), 5.77(d,J=3.0 Hz,1H), 3.35(dt,J=9.2, 3.7 Hz, 1H), 3.15 (dt,J=17.6, 5.6 Hz,1H), 2.75(m,2H), 2.54(dt,J=16.8, 5.6 Hz, 1 H), 2.02(ddd,J=17.6, 9.2, 4.5 Hz, 1H), 1.46-1.90(m,10H), 1.41(m,1H), 1.19(m,1H), 0.93(d,J=7.1 Hz,3H), 0.89(d,J=6.7 Hz,3H), 0.61(d,J=6.4 Hz,3H)ppm.

¹³ C NMR(90 MHz; CDCl₃): δ 141.7(s), 139.8(s), 138.1(s), 118.6(d), 114.1(d), 109.7(d), 49.3(d), 38.9(d), 34.8(t), 30.7(t), 27.3(d), 26.9(d), 26.7(t), 26.6(t),25.1(t), 24.0(q), 22.1(t), 21.9(t), 21.6(q), 19.8(q)ppm. minor isomer (Compound No. 1 of Table XX):

¹ H NMR(360 MHz; CDCl₃): δ 6.55(d,J=2.6 Hz,1H), 6.49(s,5H), 5.57(d,J=2.7 Hz,1H), 3.07(ddd,J=16.5, 7.0, 4.8 Hz, 1H), 2.93(dt,J=17.3, 6.7 Hz, 1H), 2.75(m,1H), 2.45(dt,J=1.72, 6.3 Hz, 1H), 1.0-2.25(m, 14H), 0.95(d,J=6.9 Hz, 3H), 0.70(d,J=6.6 Hz,3H), 0.45(d,J=6.7 Hz,3H)ppm.

¹³ C NMR (90 MHz; CDCl₃): δ 144.7(s), 144.2(s), 137.3(s), 118.4(d), 111.7(d), 106.2(d), 47.2(d), 37.5(t), 36.8(d), 32.7(t), 28.9(d), 28.3(d), 25.9(t), 25.1(t), 23.9(q), 22.3(t), 22.0(t), 21.7(t), 21.3(q), 18.9(q).,1.48(m, 4 H)ppm.

EXAMPLE 5

This Example illustrates the preparation of(η⁵ -(1R,7S)-1,3,10,10-tetramethyltricyclo- 5.2.1.0²,6 !-deca-2,5-dien-4-yl)(η⁵ -cyclopentadienyl)zirconium dichloride. (Compound No. 1 in Table XIII).

(1R,7S)-1,3,10,10-Tetramethyltricyclo 5.2.1.0²,6 !-deca-2,5-diene (0.2 g, 1.06 mmol) was dissolved in freshly distilled diethyl ether (30 ml) and cooled to 0° C. before n-butyllithium (0.44 ml, 2.5 M, 1.1 mmol) was added dropwise via a syringe to afford a yellow solution which was stirred for 4 hours at room temperature after which the solution was colourless. The lithium salt solution was added to a slurry of CpZrCl₃.DME (0.56 g, 1.59 mmol) in freshly distilled diethyl ether (10 ml) and the reaction mixture stirred at room temperature for 36 hours. The residue was filtered under argon and the filtrate reduced in volume under vacuum to yield a black oil, which was extracted with benzene (30 ml), filtered through a sinter and again reduced in volume to yield a second black oil. The product was extracted from the oil with hot (60° C.) hexane, which upon cooling afforded a dirty yellow precipitate of crude metallocene. The solid was isolated and recrystallised again from hot hexane, giving the title compound in 3.4% yield as an off-white crystalline solid with a 10:1 mixture of exo and endo isomers (15 mg, 0.04 mmol).

¹ H NMR (CDCl₃) 300 MHz: δ/ppm 6.47(s,5H), 6.07(d,J=3 Hz, 1H), 5.76(d,J=3 Hz, 1H), 2.69(d,J=4 Hz, 1H), 2.32(s,3H), 1.22(s,3H), 0.90(s,3H), 0.28(s,3H). In addition the following signals from the minor (exo) isomer (Compound No. 1 in Table XXV) could be distinguished: 6.21(d,J=3 Hz,1H), 5.91(d, J=3 Hz, 1H), 2.96(d,J=4 Hz, 1H).

EXAMPLE 6

This Example illustrates the preparation of (η⁵ -(1R,7S)-1,3,10,10-tetramethyltricyclo- 5.2.1.0²,6 !-deca-2,5-dien-4-yl)(η⁵ -cyclopentadienyl)titanium dichloride (Compound No. 2 in Table XIII).

(1R,7S)-1,3,10,10-Tetramethyltricyclo 5.2.1.0²,6 !-deca-2,5-diene (0.2 g, 1.06 mmol) was dissolved in freshly distilled tetrahydrofuran (15 ml) and n-butyllithium (0.44 ml, 2.5 M, 1.1 mmol) was added dropwise via a syringe to afford a yellow solution which was stirred for 4 hours at room temperature. The lithium salt solution was added to a stirred solution of cyclopentadienyl titanium trichloride (0.23 g, 1.05 mmol) in freshly distilled tetrahydrofuran (15 ml) and the reaction mixture stirred at room temperature for 38 hours. The solvent was removed from the reaction mixture under reduced pressure, and the dark red residue was dissolved in choroform (20 ml) in air, and concentrated hydrochloric acid (4 ml) added and stirred for 2 hours. The aqueous phase was washed with chloroform (3×10 ml) and the combined organic layers were dried (MgSO₄) and the solvent removed under reduced pressure to yield a black crude residue. Recrystallization of the crude material from a hexane/dichloromethane mixture (approx. 1:1) gave the title compound in 23% yield (90 mg, 0.24 mmol).

¹ H NMR (CDCl₃) 300 MHz: δ 6.55 (s,5H), 6.25(d,J=3 Hz,1H), 5.98(d,J=3 Hz,1H), 2.78(d,J=4 Hz, 1H), 2.52(s,3H), 2.08(m,2H), 1.64(m,1H), 1.44(m,1H), 1.23(s,3H), 0.92(s,3H), 0.32(s,3H)ppm.

¹³ C NMR (CDCl₃) 75.5 MHz: δ 162.06, 145.53, 129.44, 128.00, 119.30, 109.85, 70.35, 55.61, 51.37, 32.76, 25.61, 21.32, 20.06, 14.69, 12.81 ppm.

The following Examples illustrate how the compounds of the invention can be used in chemical reactions. Enantiomeric excesses (ee) were measured by Moschers ester analysis, by chiral gas chromatography using a chiral column (such as an Astec A-DA, or MN-CAMAG FS-Hydrodex-β-3P capillary column) or by chiral high pressure liquid chromatography using a chiral column (such as a Chiracel OD-H, OB, or chiralpak AD (Daicel)).

EXAMPLE 7

Preparation of N-Methyl-N-(2-methylthiomethyletherbutyl)aniline.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 24 mg, 0.05 mmol) was dissolved in a solution of diethylmagnesium (5.5 ml of a 0.73 M solution in diethyl ether, 4.0 mmol). N-Allyl-N-methylaniline (0.147 g, 1 mmol) was added as a solution in THF (1 ml). The resulting mixture was stirred at room temperature for 24 hours. The mixture was cooled to 0° C. and dry CH₃ SSCH₃ (1 g) in THF (1 ml) was added. The resulting mixture was poured into saturated aqueous ammonium chloride solution (100 ml) and the aqueous was extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated in vacuo to leave an oil which was purified by column chromatography (eluant 0.5% diethyl ether in petroleum ether, 2% diethyl ether in petroleum ether finally 100% diethyl ether) to give the title compound as a clear oil (0.137 g, 61%, 52% ee).

¹ H NMR (300 MHz, CDCl₃): 7.26(m,2H), 6.76(d,J=9 Hz,2H), 6.70(tt,J=7.2,1.2 Hz,1H), 3.43(dd,J=14.7,7.8 Hz,1H), 3.23(dd,J=14.7,6.9 Hz,1H), 2.99(s,3H), 2.57(d,J=5.7 Hz,2H), 2.11 (s,3H), 2.04(m,1H), 1.49(m,2H), 0.98(t,J=7.2 Hz,3H) ppm.

¹³ C NMR (75.5 MHz, CDCl₃): 149.7(s), 129.3(d), 116.1(d), 112.2(d), 56.4(t), 39.6(d), 38.6(q), 37.0(t), 24.2(t), 16.7(q), 11.2(q) ppm.

EXAMPLE 8

Preparation of N-(2-methylthiomethyletherbutyl)aniline.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 19 mg, 0.04 mmol) was dissolved in a solution of diethylmagnesium (5.7 ml of a 1.4 M solution in diethyl ether, 8 mmol). N-Allylaniline (0.266 g, 2 mmol) was added and the resulting mixture was stirred at room temperature overnight. The mixture was cooled to 0° C. and quenched with dry CH₃ SSCH₃ (1 g) in THF (2 ml). The resulting mixture was poured into saturated aqueous ammonium chloride solution (100 ml) and the aqueous was extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated in vacuo to leave an oil which was purified by column chromatography (eluant 2% diethyl ether in petroleum ether) followed by Kugelrohr distillation (70° C., 0.5 mbar) to give the title compound as a clear oil (0.399 g, 95%, 75% ee).

¹ H NMR (300 MHz, CDCl₃): 7.22(m,2H), 6.70(m,3H), 3.23(dd,J=13.0,6.5 Hz,1H), 3.17(dd,J=13.0,6.5 Hz,1H), 2.63(dd,J=12.9,5.7 Hz,1H), 2.58(dd,J=12.7,6.5 Hz), 2.13(s,3H), 1.87(sept,J=6.2 Hz,1H), 1.52(quin,J=6.2 Hz,1H), 0.99(t,J=5.0 Hz,3H) ppm.

¹³ C NMR (67.5 MHz, CDCl₃): 148.5(s), 129.4(d), 117.3(d), 112.8(d), 46.8(t), 39.2(d), 37.4(t), 24.7(t), 16.6(q), 11.2(q) ppm.

In a similar fashion (cyclopentadienyl)-(1- (1'R,2'R,5'S)-2'-isopropyl-5'-methyl cyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (as prepared in Example 2) gave the title compound in 52% yield and 79% ee; and (cyclopentadienyl)-(1- (1'R,2'R,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride gave the title compound in 73% yield and 36% ee.

EXAMPLE 9

Preparation of 2-Methylbutanol.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 24 mg, 0.05 mmol) was dissolved in a solution of diethylmagnesium (5.5 ml of a 0.73 M solution in diethyl ether, 0.04 mmol). Allylalcohol (0.058 g, immol) was added and the resulting mixture was stirred at room temperature overnight. The mnixture quenched by pouring it into a mixture of ice and ammonium chloride solution. The aqueous was extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated at atmospheric pressure to leave a crude product. The crude product was added to camphor sulphonyl chloride (0.250 g, 1 mmol) in pyridine (10 ml). The resulting mixture was stirred at room temperature overnight and then poured into water and extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated to leave an oil which was purified by column chromatography (eluant 30% diethyl ether in petroleum ether) to give the title compound as its camphor sulphonate ester (a mixture of diastereoisomers) (0.090 g, 30%, 61% ee).

¹ H NMR (300 MHz, CDCl₃): 4.12(m,2H), 3.59(d,J=15.0 Hz,1H), 2.98(d,J=15.0 Hz,1H), 2.33-2.55(m,2H), 1.15-2.13 (m,8H), 1.11(s,3H), 0.96(d,J=6.9 Hz,3H), 0.91(t,J=7.2 Hz,3H), 0.87(s,3H) ppm.

¹³ C NMR (75.5 MHz, CDCl₃): 214.7(s), 74.9(t), 58.1(s), 48.1(s), 46.6(t), 42.9(d), 42.7(t), 34.7(d), 27.0(t), 25.6(t), 19.9(q), 19.8(q), 16.2*(q), 16.1*(q), 11.1(q), 11.1(q) ppm.

* Split peaks due to diastereomers.!

EXAMPLE 10

Preparation of (3-ethyl)-1-butene-4-ol.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 19 mg, 0.04 mmol) was dissolved in a solution of ethylmagnesium bromide (2.6 ml of a 3 M solution in diethyl ether, 8 mmol). 2,5-Dihydrofuran (0.140 g, 2 mmol) was added as a solution in diethyl ether (2 ml). The resulting mixture was stirred at room temperature overnight and then poured into a mixture of ice and aqueous ammonium chloride solution. The aqueous was extracted with diethyl ether (3×50 ml) and the combined organic extracts were evaporated at atmospheric pressure to leave an oil. Camphor sulphonyl chloride (0.500 g, 2 mmol) in pyridine (10 ml) was added to the oil and the resulting mixture was stirred at room temperature overnight. The mixture was then poured into water and extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated to leave an oil which was purified by column chromatography (eluant 30% diethyl ether in petroleum ether) to give the title compound as its camphor sulphonate ester (0.138 g, 22%, 92% ee).

¹ H NMR (300 MHz, CDCl₃): 5.59(m,1H), 5.12(m,2H), 4.18(m,3H), 3.57(d,1H), 2.97(d,1H), 0.8-2.5(m,18H), 0.90(t,3H) ppm.

¹³ C NMR (75.5 MHz, CDCl₃): 214.6(s), 137.6(d), 117.8(t), 72.7(t), 58.1(s), 48.1(q), 46.9(t), 45.1(d), 42.9(d), 42.7(t), 27.0(t), 25.0(t), 23.7(t), 19.9(q), 19.8(q), 11.3(q) ppm.

EXAMPLE 11

Preparation of N-(2-hydroxymethylbutyl)-4-benzylpiperidine.

A solution of diethylmagnesium (5 ml of a 0.8 M solution in diethyl ether, 4 mmol) was placed in a Schlenk tube and the solvent removed. The residue was dissolved in THF (1 ml). (Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 24 mg, 0.05 mmol) was added under positive argon flow followed by N-allyl-4-benzylpiperidine (0.215 g, 1 mmol) in THF (1 ml). The reaction mixture was stirred at room temperature overnight. The mixture was cooled to 0° C. and a balloon of oxygen gas added. The tube was flushed through with a small amount of oxygen and the reaction mixture was stirred overnight. The reaction mixture was poured into aqueous ammonium chloride solution (100 ml) and the aqueous was extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated to leave a residue which was purified by column chromatography (eluant 20% diethyl ether in petroleum ether) followed by Kugelrohr distillation (170° C., 1.0 mbar) to give the title compound as a clear oil which crystallised on standing (0.096 g, 37%, 42% ee).

¹ H NMR (300 MHz, CDCl₃): 7.28(tt,J=6.8,1.3 Hz,2H), 7.17(m,3H), 3.77(dt,J=10.5,3.0 Hz,1H), 3.47(t,J=10.3 Hz,1H), 3. 19(d,J=11.4 Hz,1H), 2.84(d,J=11.4 Hz,1H), 2.52(d,J=7.0 Hz,2H), 2.44(d,J=2.7 Hz,1H), 2.36(t,J=12.5 Hz,1H), 2.06(td,J=11.6,2.2 Hz,2H), 1.87(m,1H), 1,68(m,2H),1.53(m,1H), 1.27(m,2H), 1.08(q,J=6.8 Hz,2H), 0.89(t,J=7.7 Hz,3H) ppm.

¹³ C NMR (75.5 MHz, CDCl₃): 140.7(s), 129.3(d), 128.4(d), 126.0(d), 69.8(t), 65.8(t), 56.3(t), 53.0(t), 43.2(t), 38.0(d), 37.4(d), 32.7(t), 32.1(t), 23.1(t), 12.0(q) ppm.

EXAMPLE 12

Preparation of N-(2-hydroxymethylbutyl)-N-phenylpiperazine.

A solution of diethylmagnesium (5 ml of a 0.8 M solution in diethyl ether, 4 mmol) was placed in a Schlenk tube and the solvent removed. The residue was dissolved in THF (1 ml). (Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 24 mg, 0.05 mmol) was added under positive argon flow followed by N-allyl-N-phenylpiperazine (0.202 g, 1 mmol) in THF (1 ml). The reaction mixture was stirred at room temperature overnight. The mixture was cooled to 0° C. and a balloon of oxygen gas added. The tube was flushed through with a small amount of oxygen and the reaction mixture was stirred overnight. The reaction mixture was poured into aqueous ammonium chloride solution (100 ml) and the aqueous was extracted with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated to leave a residue which was purified by column chromatography (eluant 20% diethyl ether in petroleum ether) followed by Kugelrohr distillation (170° C., 1.0 mbar) to give the title compound as a clear oil which crystallised on standing (0.090 g, 38%, 55% ee).

¹ H NMR (300 MHz, CDCl₃): 7.27(t,J=8.5 Hz,2H), 6.89(m,3H), 3.79(dt,J=10.5,2.4 Hz,1H), 3.53(t,J=10.3 Hz,1H), 3.20(m,4H), 2.87(m,2H), 2.54(m,4H), 1.94(m,1H), 1.14(quin,J=6.8 Hz,2H), 0.93(t,J=7.0 Hz,3H) ppm.

¹³ C NMR (75.5 MHz, CDCl₃): 151.2(s), 129.3(d), 120.1(d), 116.4(d), 69.7(t), 65.4(t), 53.9(t), 49.4(t), 37.4(d), 23.0(t), 12.0(q) ppm.

EXAMPLE 13

Preparation of N-(2-methylbutyl)aniline.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 0.042 g, 0.08 mmol) was dissolved in a solution of diethylmagnesium (7 ml of a 0.832 M solution in diethyl ether, 6 mmol). N-Allylaniline (0.266 g, 2 mmol) was added as a solution in THF (2 ml). The resulting mixture was stirred at room temperature overnight. The mixture was then slowly added (using a syringe) to concentrated hydrochloric acid at 0° C. The aqueous phase was extracted with diethyl ether. The ethereal extracts were combined, dried and evaporated to leave (cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (46 mg of 90% pure material).

The aqueous phase was then neutralised with sodium hydroxide solution (2M) and extracted again with diethyl ether (3×50 ml). The organic extracts were combined, dried and evaporated to leave an oil which was Kugelrohr distilled (155° C., >O. Imbar) to furnish the title compound as a clear oil (0.180 g, 55%).

EXAMPLE 14

Preparation of 2-ethyl-trans-4-phenyl-3-butene-1-ol, 2-ethyl-1-phenyl-3-butene-1-ol, 2-ethyl-trans-4-(4-fluorophenyl)-3-butene-1-ol and 2-ethyl-1-(4-fluorophenyl)-3-butene-1-ol. (Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (prepared as in Example 1, 48 mg, 0.1 mmol, 5 mol %) was dissolved in ethylmagnesium chloride solution (5 ml of a 2 M solution in diethyl ether, 10 mmol) at room temperature, 2-phenyl-2,5-dihydrofuiran (0.292 g, 2 mmol) in diethyl ether (2 ml) was added, and the reaction stirred at room temperature for 34 hours. The mixture was cooled and poured into ammonium chloride solution (50 ml). The products were extracted into diethyl ether, seperated by column chromatography (eluant 20% diethyl ether in petroleum ether) and Kugelrohr distilled to afford 2-ethyl-trans-4-phenyl-3-butene-1-ol (52% yield, 78% ee) and 2-ethyl-1-phenyl-3-butene-1-ol (42% yield, 82% ee). In a similar fashion, except that the reaction time was 10 hours at 40° C., 2-(4-fluorophenyl)-2,5-dihydrofuran gave 2-ethyl-trans-1-(4-fluorophenyl)-3-butene-1-ol (53% yield, 75% ee) and 2-ethyl-1-(4-fluorophenyl)-3-butene-1-ol (27% yield, 74% ee).

2-Ethyl-trans-4-(4-fluorophenyl)-3-butene-1-ol: ¹ H NMR (300 MHz; CDCl₃): δ 7.34(dd,J=8.8, 5.1 Hz, 2H), 7.00(t,J=8.0 Hz,2H), 6.46(d,J=15.5 Hz, 1H), 5.91(dd,J=16.2, 8.8 Hz, 1H), 3.66(dd,J=11.1, 5.1 Hz, 1H), 3.52(dd, J=10.3, 8.0 Hz, 1H), 2.30(m, 1H), 1.54(m,2H), 1.36(m,1H), 0.95(t,J=7.4 Hz, 3H)ppm.

¹³ C NMR (75.5 MHz; CDCl₃): δ 162.3, 133.5, 131.5, 131.3, 127.7, 115.5, 66.0, 48.2, 24.2, 11.9 ppm.

2-Ethyl-1-(4-fluorophenyl)-3-butene-1-ol: ¹ H NMR (300 MHz; CDCl₃): δ 7.30(m,2H), 7.03(t,J=8.7 Hz, 2H), 5.64(ddd, J=16.9, 9.6, 9.6 Hz, 1H), 5.30(dd,J=10.3, 1.5 Hz, 1H), 5.22(dd,J=16.9, 2.2 Hz, 1H), 4.39(d,J=7.4 Hz, 1H), 2.24(brs, 1H), 2.15(m,1H), 1.19(m,2H), 0.79(t,J=7.4 Hz, 3H)ppm.

¹³ C NMR (75.5 MHz; CDCl₃): δ 162.4, 139.05, 138.4, 128.6, 119.5, 115.2, 76.0, 55.0, 23.5, 11.9 ppm.

EXAMPLE 15

Preparation of 1-(1-pyrrolidinyl)-1-phenylethane.

(Cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!4,5,6,7-tetrahydroindenyl) titanium dichloride (22 mg, 0.05 mmol, 1 equivalent, as prepared in Example 4) was dissolved in tetrahydrofuran (5 ml) and Red-Al (0.11 ml of 33% weight solution in toluene, 0.2 mmol, 2 equivalents) added turning the red solution dark grey/purple. Phenylsilane (30 μL) was then added. This mixture was stirred at room temperature for an hour before a solution of 1-phenyl-1-(1-pyrrolidinyl)-ethene (0.173 g, 1 mmol, 20 equivalents) in tetrahydrofuran (2 ml) was added via a syringe turning the reaction brown. The reaction flask was then evacuated and refilled with hydrogen gas before being stirred overnight. The reaction was poured into water and the title compound was extracted into dilute hydrochloric acid (2M). The acid washings were then made strongly basic with sodium hydroxide and the product was extracted into diethylether. The solvent was removed to yield a yellow oil (60 mg, 34%) shown to be a 30% enantiomeric excess by NMR in the presence of (R)-O-acetylmandelic acid. (See N. E. Lee and S. L. Buchwald, J. Am. Chem. Soc. 1994, 116, 5985-6.)

When this reaction was repeated at 500 p.s.i. of hydrogen the product was isolated in 66% yield and 49% enantiomeric excess.

EXAMPLE 16

Preparation of phenyl(2-methylbutyl)sulphide.

Hexane (1 ml) was added to (cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclohexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride complex (20 mg, 4 mol %, prepared as in Example 1) in a 25 ml schlenk flask containing a stirring bar. Allylphenylthioether (150 mg, 1 mmol) was added and the flask evacuated and refilled 3 times with argon. Triethylaluminum (6 ml, 1.0 M in hexane, 6 mmol, 6 eq) was added dropwise. The solution turned yellow and was left for 72 hours. Water (10 ml) was added dropwise, the organics were extracted with diethylether (3×5 ml) and the combined extracts were dried over magnesium sulphate. The solvents were removed under reduced pressure and Kugelrohr distillation yielded the title compound as a clear liquid (145 mg, 0.85 mmnol, 80.5% yield, e.e 57% (FS-Hydrodex-B, 110° C.)).

EXAMPLE 17

Hydrogenation of 2-phenyl-1-butene.

(1R,7S)-1,3,10,10-Tetramethyltricyclo- 5.2.1 .0²,6 !-deca-2,5-dienyl)(η⁵ -cyclopentadienyl)titanium dichloride (21 mg, 0.05 mmol, prepared as in Example 6) together with 2-phenyl-1-butene (132 mg, 1 mmol) and freshly distilled toluene (5 ml) were placed into a 50 ml round-bottomed flask. After degassing with three freeze/thaw cycles the vessel was filled with hydrogen (3 evacuate/refill cycles). n-Butyllithium (0.2 ml, 22.5 M, 0.5 mmol) was then added via syringe at room temperature and the resulting dark grey/green reaction mixture was stirred under a pressure of 20 p.s.i. hydrogen, while excluding light, for 40 hours. The hydrogen pressure was vented and the reaction vessel opened to air. Aqueous hydrochloric acid (2 ml, 5 M) was added and mixture was stirred for 5 minutes. The organic phase was separated and the aqueous phase extracted with ether (3×5 ml). The combined organic phases were dried (sodium sulphate) and the solvents removed iii vacuo to provide 2-phenylbutane (56 mg, 0.42 mmol) of 10.3% ee (assessed using gas chromatography, Astec α-DA column, 65° C.).

EXAMPLE 18

Ethylalumination of 1-hexene.

To a solution of (cyclopentadienyl)(1- (1'S,2'S,5'R)-2'-isopropyl-5'-methylcyclo-hexyl!-4,5,6,7-tetrahydroindenyl)zirconium dichloride (39.7 mg. 0.08 mmol, 8 mol %, prepared as in Example 1) in dichloromethane (3 ml) was added triethylaluminium (1 ml of a 1.0 M solution in hexanes, 1 mmol) dropwise over 5 minutes at room temperature. To this solution was added 1-hexene (0.125 ml, 1 mmol) and the solution stirred at room temperature for 12 hours. Oxygen was then bubbled through the mixture for 30 minutes, after which the reaction mixture was stirred under an atmosphere of oxygen for 6 hours. Aqueous sodium hydroxide solution (10 ml, 15% solution) was then added and the products extracted into ether (3×5 ml). Removal of solvent and chromatography gave pure 2-ethyl-1-hexanol (62.6 mg, 48%) with a 25% ee (gas chromatography analysis (FS-Hydrodex-β-3P)).

EXAMPLE 19

Preparation of N-(2-methylthiomethyletherbutyl)aniline.

To a flask which had ben flame dried under vacuum, containing (η⁵ -(1R,7S)-1,3,10,10-tetramethyltricyclo 5.2.1.0²,6 !-deca-2,5-dien-4-yl)(η⁵ -cyclopentadienyl)zirconium dichloride (prepared as in Example 5, 15 mg, 0.04 mmol, 4 mol %) and allylaniline (0.125 g, 1.05 mmol) was added THF (1 ml) followed by ethylmagnesium chloride (2.6 ml of a 2.0 M solution in THF, 5.25 mmol). The reaction was stirred at room temperature in the dark for 60 hours before addition of dimethylsulphide (1 ml) and work-up as in Example 8, to give the title compound (60 mg, 35% yield, 29.6% ee). ##STR2## 

We claim:
 1. A chiral, organometallic compound which, at a molecular level, has no C2 symmetry characterised in that the organometallic compound has the general chemical formula (I): wherein X¹ and X² are, independently, groups which are removable during a chemical reaction;M is titanium, zirconium or hafnium; and (a) R⁸ and R¹¹ are hydrogen; R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylakyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylakly, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with hydroxy, trialkylsilyl, alkyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalky, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³ is as defined for R¹ ; R⁴, R⁵, R⁶ and R⁷ are the same or different and are hydrogen or as defined above for R¹ ; or one or more of R³ and R⁴, R⁴ and R⁷ or R⁵ and R⁶ join to formn an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally substituted silyl bridge; or (b) R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms and R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyaryloxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹, R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms and R² is hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; one of R⁴ and R¹¹ is hydrogen, the other being trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyaryloxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R⁵, R⁶ and R⁷ may be the same or different and are selected from the substitiuents already recited for R² ; or, one or more of R⁵ and R⁶ or R⁷ and whichever of R⁴ and R¹¹ is not hydrogen to join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatams; or R⁵ joins with one of R⁶, R⁷ or whichever of R⁴ and R¹¹ is not hydrogen to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge.
 2. A compound as claimed in claim 1 having the formula (Ia): ##STR3## wherein R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalky, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with hydroxy, trialkylsilyl, alkyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³ is as defined for R¹ ; R⁴, R⁵, R⁶ and R⁷ are the same or different and are hydrogen or as defined above for R¹ ; or one or more of R³ and R⁴, R⁴ and R⁷ or R⁵ and R⁶ join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally silyl bridge; X¹ and X² are, independently, groups which are removable during a chemical reaction; and M is titanium, zirconium or hafnium.
 3. A compound as claimed in claim 1 having the formula (Ia): ##STR4## wherein R¹ and R² are different and are trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl or C₃₋₈ heterocyclyl ring optionally substituted with hydroxy, trialkylsilyl, alkyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R³ as defined for R¹ ; R⁴, R⁵ and R⁶ are the same or different and are hydrogen or as defined for R¹ above; or R³ and R⁴ or R⁵ and R⁶ or both join to form an optionally substituted saturated or unsaturated ring comprising one or more heteroatoms; R⁷ is hydrogen or alkyl; or R³, R⁴ or R⁷ joins with R⁵ to form an optionally substituted C₁₋₃ alkyl or optionally silyl bridge; X¹ and X² are, independently, groups which are removable during a chemical reaction; and M is titanium, zirconium or hafnium.
 4. A compound as claimed in claim 1 having the formula (Ib): ##STR5## wherein X¹ and X² are, independently, groups which are removable during a chemical reaction;M is titanium, zirconium or hafnium; R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms and R¹ and R² are different and are hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; or R¹, R³ and R⁸ join to form an optionally substituted non-aromatic ring system optionally comprising one or more heteroatoms and R² is hydrogen, trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; one of R⁴ and R¹¹ is hydrogen, the other being trialkylsilyl, alkyl, aryl, arylalkyl, aryloxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl or heteroaryloxyalkyl; R⁵, R⁶ and R⁷ may be the same or different and are selected from the substituents already recited for R² ; or, one or more of R⁵ and R⁶ or R⁷ and whichever of R⁴ and R¹¹ is not hydrogen join to form an optionally substituted saturated or unsaturated ring optionally comprising one or more heteroatoms, or R⁵ joins with one of R³, R⁷ or whichever of R⁴ and R¹¹ is not hydrogen to form an optionally substituted C₁₋₃ alkyl bridge or optionally substituted silyl bridge.
 5. A compound as claimed in claim 1, 2, or 3 wherein R³ and R⁴ or R⁵ and R⁶ or both join to form an optionally substituted unsaturated or saturated ring comprising one or more heteroatoms.
 6. A compound as claimed in claim 1, 2, 3 or 5 wherein R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring.
 7. A compound as claimed in claim 1, 2, 3 or 5 wherein R³ is C₁₋₄ alkyl; R⁴ is hydrogen or C₁₋₄ alkyl; or R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 5, 6 or 7 membered non-aromatic carbocyclic ring; and R⁷ is hydrogen or C₁₋₄ alkyl.
 8. A compound as claimed in claim 1, 2, or 3 wherein R¹ is C₁₋₄ alkyl, phenyl, tri(C₁₋₄ alkyl)silyl or phenyl(C₁₋₄)alkyl; and R² is C₁₋₄ alkyl; or R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl ring optionally substituted with alkyl or phenylalkyl.
 9. A compound as claimed in any one of claims 1 to 4 wherein R⁷ is hydrogen.
 10. A compound as claimed in claim 1 or 4 wherein when R¹¹ is hydrogen R⁴ and R⁷ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring; or when R⁴ is hydrogen R¹¹ and R⁷ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring.
 11. A compound as claimed in any one of claims 4 to 10 wherein R⁵ and R⁶ join to form an optionally substituted unsaturated or saturated ring optionally comprising one or more heteroatoms.
 12. A compound as claimed in any one of claims 1 to 4 wherein R⁵ and R⁶ are both hydrogen.
 13. A compound as claimed in any one of claims 1 to 4 wherein X¹ and X² are, independently, halogen, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl or aryloxy.
 14. A compound as claimed in claim 13 wherein X¹ and X² are, independently, halogen.
 15. A compound as claimed in any one of claims 1 to 4 wherein M is zirconium.
 16. A compound as claimed in claim 2 or 3 wherein R¹ and R² join to form an asymmetrically substituted C₃₋₈ cycloalkyl ring optionally substituted with alkyl or phenylalkyl; R³ and R⁴ join together to form (in conjunction with the cyclopentadiene ring to which they are attached) a 6 membered non-aromatic carbocyclic ring; R⁵, R⁶ and R⁷ are all hydrogen; and X¹ and X² are, independently, chlorine or bromine.
 17. A compound of formula (II) or (II'): ##STR6## or an enantiomer thereof, wherein R⁵ is hydrogen or C₁₋₄ alkyl; M is zirconium, titanium or hafnium; Y¹ is C₁₋₆ alkyl, tri(C₁₋₄)alkylsilyl or phenyl(C₁₋₄)alkyl; Y², Y³, Y⁴, Y⁵, Y⁶ and Y⁷ are all hydrogen; Y⁸ and Y⁹ are, independently, hydrogen or C₁₋₄ alkyl; and Y¹⁰ is hydrogen, C₁₋₄ alkyl or tri(C₁₋₄)alkylsilyl.
 18. A compound as claimed in any one of claims 17 or 1 to 4 which is bound to a polymer support.
 19. A process for preparing a compound as claimed in claim 1, the process comprising either:(a) deprotonating a compound of formula (III) ##STR7## and reacting the product obtained with a compound of formula (IV) ##STR8## wherein R1 to R8, M, X¹, X2 are as defined in claim 22 and L is a suitable leaving group; (b) deprotonating a compound of formula (V) ##STR9## and reacting the product obtained with a compound of formula (VI) ##STR10## wherein R¹ to R⁸, L, M, X¹ and X² are as defined above; (c) reacting a trialkylsilyl or trialkylstannyl derivative of a compound of formula (III) ##STR11## with a compound of formula (IV) ##STR12## wherein R¹ to R⁸, L, M, X¹ and X² are as defined above; (d) reacting a trialkylsilyl or trialkylstannyl derivative of a compound of formula (V) ##STR13## with a compound of formula (VI) ##STR14## wherein R¹ to R⁸, M, L, X¹ and X² are as defined above; e) when R³ and R⁴ join to form a saturated, non-aromatic, carbocyclic ring, hydrogenating a compound of formula (I) ##STR15## wherein R³ and R⁴ join to form an aromatic ring, under suitable conditions, wherein R¹, R², R⁵, R⁶, R⁷, R⁸, M, X¹ and X² are as defined above; or (f) when R³ and R⁴ form a saturated ring and M is titanium, chemically modifying the nature the ligand incorporating R³ and R⁴ whilst the ligand is attached to zirconium, removing the ligand from zirconium with a suitable base and attaching the ligand to a compound of formula (IV) ##STR16## wherein R¹, R², R⁵, R⁶, R⁷, R⁸, L, M, X¹ and X² are as defined above. 